Canada · Coverage

Renewing GLP-1 coverage in Canada: public plans and private insurers

Pending medical review

Applies to: Canada

By Joshua Nichvolodoff · Fact-checked against sources November 2, 2026 · Next review due January 31, 2027

Clinical review: not yet reviewed by a clinician. How review works · Editorial policy

Whether your GLP-1 coverage needs renewing in Canada depends on who pays: a provincial plan or a private insurer. Here is what BC and Ontario publish, what two private insurers' forms ask for at renewal, and what to gather. It can't tell you whether you qualify — only your plan decides that.

British Columbia

Special Authority requests are submitted by prescribers, not patients; the current turnaround for faxed requests is 4 weeks, and coverage is not backdated[5]. Semaglutide is covered for type 2 diabetes after inadequate control on metformin, with an indefinite approval period — so there is no periodic renewal for that coverage[1][6].

Ontario

Ozempic became a Limited Use benefit on January 31, 2024, for adults with type 2 diabetes, with an indefinite authorization period — no Limited Use renewal is required[2]. For drugs outside the formulary, only a physician or nurse practitioner can apply to the Exceptional Access Program, and how long coverage lasts depends on the drug and condition[7].

Private insurers

Express Scripts Canada's Wegovy form asks, for an adult renewal, for documented loss of 5% or more of body weight, with baseline and current weights and dates[3]. Desjardins' form for obesity medications asks, at renewal, for weight, height and BMI at the start of treatment and from the most recent visit, and confirmation of a reduced-calorie diet and physical activity; continuing beyond the authorized period needs a new request[4]. Canada Life added Wegovy to its prior authorization program in 2023[8]. Always use your own insurer's current form, unaltered.

If a request or renewal is declined, questions to ask your insurer, plan or prescriber's office:

  • Which criterion wasn't met, or which document or measurement was missing?
  • Can my prescriber send more information or a new request, and is there a deadline?
  • Is there a review or appeal process, and how do I start it?
  • Is a different form, program or exception available for my situation?

Asking doesn't change the criteria or promise a different decision. It helps you and your prescriber see what's missing.

What to gather before your authorization ends

  • Your approval letter or notice: the drug, the authorized period, and any reference number.
  • Your starting weight, height and the date; your most recent weight and the date.
  • Your insurer's current prior authorization form (linked from its website or your plan booklet).
  • The date to contact your prescriber — renewals are completed by your prescriber's office.
  1. Prior authorization endsfrom your plan's approval letter
  2. Prescription expiresfrom your pharmacy label or pharmacist
  3. Next refill duefrom your own supply
  4. Appeal deadlineonly if you were denied — from the denial letter
Four different dates, in no fixed order. A valid prescription doesn't mean coverage is approved, and an approval doesn't renew your prescription.

To keep track of these in one place, use the coverage renewal brief — a blank checklist that keeps the dates apart and prints a summary for your prescriber. It stays in your browser.

General information, not legal, insurance or medical advice. Criteria and forms change; your plan decides.

Sources

  1. Limited coverage criteria — semaglutide. Province of British Columbia (PharmaCare), April 21, 2026. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/programs/limited-coverage-drug-program/limited-coverage-drugs-semaglutide. Accessed November 2, 2026. Back to the text
  2. Executive Officer notice: update to Ozempic listing — change in status to Limited Use benefit. Ontario Ministry of Health, January 26, 2024. https://www.ontario.ca/files/2024-01/moh-executive-officer-notice-en-2024-01-26.pdf. Accessed November 2, 2026. Back to the text
  3. Prior authorization request — WEGOVY (semaglutide) (blank form). Express Scripts Canada, July 28, 2026. https://www.express-scripts.ca/sites/default/files/paf/en/WEGOVY%20(semaglutide)%20-%20EN.pdf. Accessed November 2, 2026. Back to the text
  4. Prior authorization request — Contrave, Saxenda, Wegovy, Xenical, Zepbound (form 12607E, 2026-09) (blank form). Desjardins Insurance, September 2026. https://www.desjardins.com/content/dam/pdf/en/personal/insurance/health-dental/drug-prior-authorization/12607E.pdf. Accessed November 2, 2026. Back to the text
  5. Special Authority. Province of British Columbia (PharmaCare), October 30, 2026. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/programs/special-authority. Accessed November 2, 2026. Back to the text
  6. Special Authority Request — Semaglutide for Diabetes (HLTH 5826). BC Ministry of Health, February 13, 2026. https://www2.gov.bc.ca/assets/gov/health/forms/5826fil.pdf. Accessed November 2, 2026. Back to the text
  7. Faire une demande au Programme d’accès exceptionnel (Exceptional Access Program). Government of Ontario, October 18, 2023. https://www.ontario.ca/fr/page/faire-une-demande-au-programme-dacces-exceptionnel. Accessed November 2, 2026. Back to the text
  8. Updates to Ozempic and Rybelsus (semaglutide) coverage coming soon. Canada Life, September 12, 2023. https://www.canadalife.com/content/dam/group-customer/Semaglutide-coverage-updates-sponsors.pdf. Accessed November 2, 2026. Back to the text

Figures marked “as reported” are historical: they show what the source said on that date, not today's price or rule.

Changes to this page

  • — First published.

Substantive corrections are also logged at corrections.